These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 23043142)

  • 1. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
    Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
    Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Fiorenzato E; Antonini A; Bisiacchi P; Weis L; Biundo R
    Mov Disord; 2021 Oct; 36(10):2303-2313. PubMed ID: 34124799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
    Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
    J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
    Song IU; Chung YA; Oh JK; Chung SW
    Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.
    Erro R; Pappatà S; Amboni M; Vicidomini C; Longo K; Santangelo G; Picillo M; Vitale C; Moccia M; Giordano F; Brunetti A; Pellecchia MT; Salvatore M; Barone P
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1034-8. PubMed ID: 22789824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of Asymmetry of Nigrostriatal Dopaminergic Function in Healthy Subjects.
    Garrido A; Iranzo A; Stefani A; Serradell M; Muñoz-Lopetegi A; Marrero P; Högl B; Gaig C; Santamaria J; Tolosa E; Poewe W;
    Mov Disord; 2020 Jun; 35(6):1072-1076. PubMed ID: 32141653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE
    J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.
    Roos DS; Twisk JWR; Raijmakers PGHM; Doty RL; Berendse HW
    J Neural Transm (Vienna); 2019 Nov; 126(11):1471-1478. PubMed ID: 31515655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of overactive bladder with motor symptoms and dopamine transporter imaging in drug-naïve Parkinson's disease.
    Mito Y; Yabe I; Yaguchi H; Takei T; Terae S; Tajima Y
    Parkinsonism Relat Disord; 2018 May; 50():37-41. PubMed ID: 29449184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.